




版權說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權,請進行舉報或認領
文檔簡介
應用DHPLC技術進行診斷性分析的質量保證體系張澤云美國環(huán)球基因公司中國代表處診斷性分析的要求臨床分子遺傳學分析的復雜性臨床分子檢測結果的一致性和精確性
變性高效液相色譜(DHPLC)作為一種高效和敏感的基因突變檢測技術DHPLC技術質量控制AMERICANCOLLEGEOFMEDICALGENETICS
StandardsandGuidelinesforClinicalGeneticsLaboratories
2005Edition
G:CLINICALMOLECULARGENETICS
TheseStandardsandGuidelinesspecificallyrefertotheuseofmoleculartechniquestoexamineheritableorsomaticchangesinthehumangenome.
G18
DenaturingHighPerformanceLiquidChromatography(dHPLC)
(SectionAddedNovember2003)CMGSBestPracticeGuidelinesUseoftheWAVESysteminDiagnosticService
PreparedandeditedbyJohnHarvey,NationalGeneticsReferenceLaboratory(Wessex),Salisbury,UKandElsSchollen,CentreforHumanGenetics,Leuven,Belgium
lastupdate:12March2004
?Introduction
?Laboratoryprocess
?DHPLCsystem
?Dataquality
?Checking&reporting
guidelines
?References
DHPLCSOPsInstrumentormaintenance
SOPTechnique
GeneralDHPLCSOPWAVE3500,3500HTMethod
Disease-specificSOPsRett,BRCA,HNPCC
Marfan,…Applicationcompany+usersgeneralusers+companyspecificusers
SupplementaryAppendix1
STANDARDOPERATINGPROCEDUREWAVE?SystemOperationandMaintenance
SOP-O&M
WAVE?SystemOperationandMaintenance
ForWAVE?SystemModels3500,3500Aand3500HTWAVE?SystemOperationandMaintenance
AnalysisoftheWAVE?Low&HighRangeMutationStandardsThemaintenanceprocedureDNASep?andDNASep?HTcartridgemaintenance
RoleofMutationstandards:
checkingofcorrectfunctioningoftheWAVE?System,includingovencalibration,cartridgeperformance,buffercompositionandstability,toensurereproducibilityandaccuracyofthechromatographicanalysis.
Mutationstandardsberunwhen:
l
Theroutinepre-run,
l
Weeklyandmonthlymaintenanceprocedure,
l
Afterreplacementofanycomponent,
l
Validationforanewbatch,
l
Asanassaycontrol,atthebeginningandendofeveryrun,preferablyalsoafterevery100injectionsforlongruns.
AnalysisoftheWAVE?Low&HighRangeMutationStandards
NormalrangesofthemutationstandardsThemaintenanceprocedure3.1Filterandflush3.2Pre-runmaintenance3.3Weeklymaintenance3.4Quarterlymaintenance3.5Othermaintenanceoperations3.6Preventativemaintenanceprocedureandsystemvalidation
Filterandflush
Theprincipleoffiltrationinvolvespreventingunwantedcontaminantsfromenteringthesystem.Filtrationappliestotwospecificareas:solventfiltrationandin-linefiltration.Thesystemflushingistoremovemobilephasesaltcomponentsthatcanprecipitateunderstrongsolventconditions.
Pre-runmaintenance1.Buffercheck2.Injectionsystemwashing3.Pressurecheck4.Checktheabsorbanceonthedetector5.Purgethelines
WeeklymaintenanceInlinefilterreplacement
Checkthesyringe
Quarterlymaintenance
CheckUVlamp
UVlampreplacement
Cleaningthesystem(Isopropanolcleaning)
DNASep?andDNASep?HTcartridgemaintenance
1.
Regularmaintenanceschedule
Every96-192injections:Extendedhotwash
Every1000injections:Reversehotwash
DNASep?wash(ifreversehotwashfailstoresolvemutationstandards)2.Short-termcartridgestorage3.Long-Termcartridgestorage4.NewcartridgeinstallationDailyMaintenanceEquilibratethecartridge50%A50%Bfor15minutesRun1-2blanksVerifysystemperformance(pre-analysis)RunastandardRunSamplesVerifysystemperformance(postanalysis)WeeklyMaintenanceAnExtendedActiveCleanWashisrecommendedevery~100injections.(Usuallydoneaftereach96wellplate)OvenSetto:80°CPumpSetto:100%D15-30minutesWASHOvenSetto:56°CPumpSetto:50%A-50%BEQUILIBRATE45-90minutesRunStandardstoVerifySystemPerformance!1000InjectionMaintenanceAReverseHotWashisrecommendedevery~1000injectionsUV/FLDetector
TurnoffthepumpReversethecartridgedirection.Settheovento80°C.Setthepumpto100%D.60-90minutesStoringtheCartridgeFlushthecartridgewith100%DBuffer.RemovethecartridgefromtheWAVESystem.Capthecartridgewithendplugs.Storethecartridgeatroomtemperature.InstallingaNewCartridgeStopthepumpflowandremovetheoldcartridge.Removetheplugsfromthenewcartridge.Installthenewcartridgewiththearrowpointingtowardtherearoftheoven.UV/FLDetectorMakesuretheovenheatsuptoatleast40°C.Setthepumpto100%D@0.500mL/min.Ensurethepressureisstableandgraduallyincreasetheflow(0.9mL/minor1.5mL/min).Flushthecartridgefor15minutes.Setthepumpto50%BufferA,50%BufferBandequilibratefor30minutes.EquilibratingaNewCartridge100%50%50%VerifyNewCartridgePerformanceLow-RangeMutationStandardDNASizingControlStandard
SupplementaryAppendix2STANDARDOPERATINGPROCEDUREDHPLCSOP-DHPLC
DHPLCmutationdetectiononTransgenomicWAVE?System3500Wavemaker?4.1.44&HSM3.0-2.1(build2)Navigator?1.5.4(build19)
PCRrequirementsPrimerdesignTemplatepurityandconcentrationDNAPolymerasesPCRbuffermixPCRplatesPCRqualityandProductmixingPost-PCR,filmuseControlsPrimerDesignUseaprimer-pickingprogramPrimersshouldideallybenocloserthan30-50bpfromtheendofthesequencetobeanalyzedformutationsPrimersshouldbe18-30bpinlengthTheTmdifferencebetweenprimersinapairshouldideallybelessthan2°C.SizeofPCRfragmentTheoptimalsizerangefordetectingmutation/SNPsbyDHPLCwith100%accuracyis150-500bp.Fragments>500bpcanbegeneratedbutsensitivitydecreasedandtimeofelutionincreased.Forfragments<150bp,differenceofmeltingpointbetweenfragmentstoonarrow(thefragmentsmeltovertoonarrowatemperaturerange).QuantityofPCRfragmentThePCRproductshouldbesufficientlyconcentratedthat2μlrunonanagarosegelproducesaclearlyvisibleband(~20ng/μl)Dilutesamples(verylowyields)producepoorqualityresults(poorsignal:noiseratio).Veryhighyieldscanleadtolargeproportionsofmisincorporationsandhenceincreaseddifficultyincallingmutations.Usually3-10μl(~50-200ng)ofunpurifiedPCRproductwouldbeinjectedontothecolumn(peronetemperature).A8μlminimumaliquotofPCRproductshouldbesuppliedinPCRtubesinstripsof8(peronetemperature).SamplePreparationforDHPLCDNAmustbeclean,allcellulardebrisandorganiccompoundsmustberemoved.Saltingoutmethodispreferred.DNAextractedwithsomecommercialsystemsmaybedilutedto10ngtoreduceeffectsofimpuritiestoPCR.DNAoflowqualitywillresultinsub-optimalPCRresults(henceDHPLCprofiles).DNAquality&concentrarionTable1.RecommendedcleaningproceduresforDNAextraction.IsolationMethodRecommendedAdditionalCleaning:OrganicExtraction
(e.g.phenol/chloroform)Chloroform/isoamylback-extractionfollowedbyethanolprecipitationandwashChaotropicSalts
(e.g.guanidiniumisothiocyanate)EthanolprecipitationandwashSpinColumnEthanolprecipitationandwashTable2.RecommendedDNAquantitiesusedforPCR(50μLreaction).TemplateRecommendedQuantityHumangenomicDNA50-200ngPhageDNA1-10pgPlasmidDNA0.1-1.0pgTheImportanceofPolymeraseFidelityforMutationDetectionImportanceofhighfidelityindHPLC500bpWildTypeFragmentRedTrace–OptimasePolymeraseGreenTrace–9:1MixAmplitaqGoldandPfuTurboHeteroduplexduetomisincorporationPolymeraseFidelityComparisonMaximumrecommendedconcentrations
ofacceptablePCRadditivesAcceptableadditives(maximumfinalconcentration)Additiveswherefinalconcentrationmustbe<1%10%
DMSOHighMolecularweightstabilizers:-polyethyleneglycol(PEG)2%
GlycerolDetergentsincludingbutnotlimitedto:TritionX100-NP40Tween20-SDS/SLS1.25to2.5M
BetaineUseofthesecomponentsrequirestheuseof'Activeclean'foreachinjection,andotheradditionalcleaning.Fluorescentlabelswillnotdamagethecolumnbutarenotrecommended.Digoxigenin/biotinlabelledprimershavenotbeentested.UnacceptablePCRcomponents.TemplateDNAextractedorpurifiedinamannernotconsistentwithWAVE’srecommendationGelpurificationcannotbeusedtocleanupsamplesforDHPLC,asthereagentsandresidualagarosedamagethecolumn.Unidentifiedreagent:“proprietary” -“stabilizers”“enhancers” -“additives”AutoclavedWaterMineralOilFormamideProteinaseKBovineserumalbumin(BSA)Loadingdyes(cresolred)(ComponentscausingirreversibleDNASepcartridgedamage)AnalysisofPCRProductsontheWAVESystemRunPCRProductsat50°C(non-denaturingconditions)toverifysize,yieldandpurityRunPCRProductsunderpartially-denaturingconditionstoverifyfidelity.Controls
PCRPositivecontrols
PCRNegativecontrolsInstrumentcontrols:LowandHighRangeMutationstandardsControlsamplesinDHPLCWhereverpossible,aconfirmedwild-typecontrolshouldberun,andcomparedwitheachsample.Amutation(positive)controlshouldbeincluded.Whenamplifyinglargenumbersofsamplesformanydifferentgenefragmentswithalowfrequencymutationpickuprate,itissometimesacceptabletoomitanormalcontrol.InstrumentBuffersCommercialbuffersPreparationof‘In-house’Buffers
Heteroduplexformation
·
Allsamplesmustbeheteroduplexed;·Heteroduplexformation:95oCfor5minandcoolslowly(minimum10s/°C)toroomtemperature.
·Fastercoolingprotocolsusedforheteroduplexformationcanseriouslyimpairheteroduplexing.·
PurificationofPCRproductscanseriouslyimpairheteroduplexformation.
SoftwareWaveMaker?4.1.44
Navigator?
ProjectSet-upSelectionofanalysistemperaturesbasedonmeltprofilesAdjustmentofgradientswithtimeshifts.
ResultsInterpretation
ChromatogramControlsMinimumpeakintensityVisualassessmentofchromatogramsTracespecifity
AssessmentofchromatogramqualityA:ContainsunincorporatednucleotidesandprimerswhichdonotbindtothecolumB:ContainsprimerdimersC:MaybecausedeitherbyTaqerrorsduringPCRorbynon-templateAaddition.D:Themajorityofwildtypesamplesappearasasinglepeak.E:ACNabsorbsat260nm.AnyhighMWcontaminantsappearasspikesonthispeak.Typicalhomozygouswild-typechromatogramACBDERetentiontime(minutes)A260nmInjectionpeakACNwashpeakSamplepeakControlsCheckthemutationstandardsandseeiftheyfulfilthecriteriadescribedinSOP-O&M.Checktheknownsequencevariants(positivecontrols).Iftheydonotpresentanaberrantchromatogramattheoptimalscreeningtemperature,theresultsshouldberejectedandtheanalysisrepeatedIdeallythesignalintensityofDHPLCprofilesshouldbe>2mVatA260.Peaksofintensity>30%oftheaveragepeakintensity.Weakpeaksaremorelikelytoleadtofalse-negative/positiveresults.MinimumpeakintensityIdentificationofsequencevariantsThepresenceofheteroduplexesisoftendetectedasachangeinthenumberofpeaks(maybe2,3or4peakpattern).Twopeakpatternsaccountforthemajorityofmutations.Completeresolutionofthe2heteroduplexesisnotalwaysnecessary.Mutationsmayappearonlyasaslightbroadeningofthesinglepeak,orasasubtlechangetoashoulderonthepeak.AllsamplesidentifiedasheteroduplexesbyDHPLCanalysismustbesequencedinbothdirectionstoconfirmanddeterminethenatureofthesequencechange.Thehomoduplexwild-typepatternistypically1peak,butmaybe2peaks,dependinguponthemeltingprofile.Elutionprofilesthatdifferfromthewild-typeindicatethepresenceofDNAsequencechanges.Butthemutationtypecannotbepredictedfromtheheteroduplexpattern.EachmutationinagivenPCRfragmentispredictedtohaveauniqueheteroduplexpattern(highlyspecificelutionprofile).Thisisusefulforquickgenotypingofunknownsamplesbycomparisonwithpositivecontrolsamples.However,traceprofilesarenotalwaysuniqueforaspecificmutation,i.e.differentDNAvariantscangiveidenticalprofiles.Changesinretentiontimedonotaccuratelypredictthepresenceofasequencechange.TracespecificityDatachecking,reportingandstorage
DatacheckingPositiveresultsFalsepositiveresultsNegativeresultsFalsenegativeresultsSensitivityDetectionofmosaicsArchiving
SupplementaryAppendix3STANDARDOPERATINGPROCEDUREMECP2SOP-MECP2
DHPLCscreeningofMECP2InthecontextofRettSyndromeRettsyndrome
Childhoodneurodevelopmentdisorderwithaprevalenceof1/10.000to1/15.000infemalebirthsMutationsintheMECP2gene,codingforMethylCpGBindingProtein2,aretheprimarycauseofRTT
Eightmutationsarerecurrentlyfoundindifferentpopulations.ThefirstpartofthemoleculardiagnosisofRTTistheDHPLC-screeningofexons2,3and4ofMECP2.Thisallowstheidentificationofmorethan90%ofalldescribedmutations.Materials
Worksheet:-
LotNo.ofallproducts-
Equipmentidentifiers-
Patient-identifier-
Performingtechnician(s)-
DateofexperimentsMaterialsPCR
-
StandardPCRequipment(Locationxxx)
-
Optimase?DNApolymerase(2.5U/μl)(Locationxxx)
-
Optimase?PCRbufferwithMg2+
(Locationxxx)
-
Primers(Eurogentec)(stock)as250pmol/μl.(appendixA)(Locationxxx)
-
Primerworksolutionscontain2.5pmol/μlofeachprimer(Locationxxx)
-
PuredNTPs(withoutdUTP)(2mM)(Locationxxx)
-
PCRsystemMaterials
DHPLCsystem
-
StandardDHPLCmaterial(forpartnumbersseeappendixCinSOP-O&M)-
WAVE?System3500HT,WAVEMAKER?4.1.44&HSM3.0-2.1build2.
Patientmaterial
-
PatientDNA
-
Positivecontrols
-
Negativecontrols
-
Normalcontrols
UsesofPlasmidControlsasReferenceReagents
noethicalproblems renewableresource CanusesamereferencereagentascontrolforPCR, heteroduplexandmutationdetectionanalysisUniversalreagentswhichcanbeincorporatedinQC proceduresandSOPsAdvantages:
Validationofnewprotocols
Exonspecificwildtypeandmutatedcontrolsforexistingassays
Validationoftransferofprotocolsbetweenmachines/labsUses:Method
Pre-PCR
PCRComposition
PCRConditions
PostPCR
Heteroduplexformation
Agarosegelelectrophoresis
DHPLC
Interpretationoftheresults
ThemutationstandardsatthebeginningandendoftherunareevaluatedAllpositivecontrolsshouldbevisibleattheirspecifictemperatureIfoneofthecontrolsdoesnotfulfillthecriteria,negativeresultsarenotvalidandhavetoberepeated.Positiveresultscanbeprocessedasusual.TheelutionprofilesofaspecificfragmentfromthedifferentpatientsarecomparedwitheachotherandscoredaccordingtothegeneralDHPLCcriteria.Theminimumpeakheightmustbe2mV.Anyparticularobservationshouldbenotedonworksheetsortechnicalreports.Ampliconswithanaberrantelutionpatternarere-analysedbydirectsequencingonanindependentampliconInterpretationoftheresults
Allprematuretruncationmutationsareimmediatelyreportable.Thepathogenicityofthemissensemutationswilldependonthepositionandthetype.Interpretationisthensubjecttogoodpracticeandliteraturereview.MutationsinthetwohighlyconservedMeCP2domains,themethylbindingdomainandthetranscriptionrepressiondomain,arelikelytobecausative.Ifamutationisofunknownsignificance,samplesshouldbeobtainedfromthepatient’sparents.Ifthemutationisfoundtobedenovo,itislikelytobecausative.Ifthemutationispresentinthemother,X-inactivationstudiesneedtobecarriedoutonthemotherofthepatientIfboththemotherandthedaughterhaverandomX-inactivationthemutationisunlikelytobecausative.Reportingprocedures
NEGATIVERESULTINAFEMALENEGATIVERESULTINAMALENORMALPARENTPOSITIVERESULTINAFEMALENEGATIVERESULTINAFEMALE
RettsyndromeiscausedbymutationsintheMECP2gene.Molecularanalysisofthisgenehasbeencarriedoutonpatient******,howevernocausativemutationhasbeenfound.
DHPLCanalysiswasusedtoscreenformutationsintheMECP2gene.Thistechniquehasasensitivityof>95%forthedetectionofpointmutations,microdeletionsandmicroinsertionsbutwillnotdetectgrossdeletionsofentireexons.Only~80%ofRettsyndromepatientshaveadetectablemutationwithintheMECP2gene.NEGATIVERESULTINAMALE
MolecularanalysisoftheMECP2genehasbeencarriedoutonpatient******.Howevernocausativemutationhasbeenfound.
DHPLCanalysiswasusedtoscreenformutationsintheMECP2gene.Thistechniquehasasensitivityof>95%forthedetectionofpointmutations,microdeletionsandmicroinsert
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經(jīng)權益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
- 6. 下載文件中如有侵權或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 院內(nèi)醫(yī)生急救培訓
- 幼兒園大班科學《會發(fā)光的物體》課件
- 平湖市臨港能源有限公司介紹企業(yè)發(fā)展分析報告
- 危險裝置評估報告模板
- 衛(wèi)生保健年度工作亮點匯報
- 講究衛(wèi)生關注健康
- 青年文化講堂策劃方案范文
- 2025年智能建筑系統(tǒng)集成節(jié)能降耗在數(shù)據(jù)中心產(chǎn)業(yè)布局中的應用研究報告
- 學校專業(yè)課件介紹
- 臨床營養(yǎng)學心腦血管疾病干預策略
- 特崗教師科學試題及答案
- 抖音員工合同協(xié)議
- 銀行培訓中心管理制度
- 鋰電池基礎知識培訓單選題100道及答案
- 2025年陜西省八年級中考三模生物試題(原卷版+解析版)
- 高分子化學材料結構與性能試題及答案
- 客服質檢管理競聘述職報告
- 2025至2030年中國木瓜酶膠囊數(shù)據(jù)監(jiān)測研究報告
- 郵件分揀員(國內(nèi)郵件分揀)中級
- 雞湯來嘍完整臺詞
- 中醫(yī)醫(yī)療技術的醫(yī)院感染控制制度
評論
0/150
提交評論